Literature DB >> 23357137

Lipoprotein apheresis--more than just cholesterol reduction?

Claas L Neumann1, Egbert G Schulz, Gerit C Hagenah, Ulf Platzer, E Wieland, Volker Schettler.   

Abstract

Lipoprotein apheresis is a well-established extracorporeal treatment in modality of severe hyperlipoproteinemia. Besides the reduction of LDL cholesterol and modifications to physiology of lipoprotein and lipid metabolism, Lipoprotein apheresis may have crucial effects on many other atherogenic factors as vascular inflammation, rheology and gene expressions in blood cells. These different effects of lipoprotein apheresis treatments are reviewed with respect to oxidative stress in plasma, red and white blood cells and in consequence to progression of atherosclerosis. However, in consideration of these reviewed aspects as a factor of biocompatibility lipoprotein apheresis remains safe.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23357137     DOI: 10.1016/j.atherosclerosissup.2012.10.017

Source DB:  PubMed          Journal:  Atheroscler Suppl        ISSN: 1567-5688            Impact factor:   3.235


  6 in total

1.  [Therapeutic algorithm for lipoprotein apheresis and PCSK9 inhibition for severe hypercholesterolemia or isolated lipoprotein(a) hyperlipoproteinemia].

Authors:  V J J Schettler; J Ringel; S Jacob; U Julius; R Klingel; F Heigl; E Roeseler; P Grützmacher
Journal:  Internist (Berl)       Date:  2016-05       Impact factor: 0.743

2.  Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels.

Authors:  Volker J J Schettler; Class L Neumann; Christian Peter; Thomas Zimmermann; Ulrich Julius; Eberhard Roeseler; Franz Heigl
Journal:  Clin Res Cardiol Suppl       Date:  2015-04

3.  The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.

Authors:  V J J Schettler; C L Neumann; C Peter; T Zimmermann; U Julius; E Roeseler; F Heigl; P Grützmacher; H Blume; A Vogt
Journal:  Clin Res Cardiol Suppl       Date:  2017-03

4.  Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients.

Authors:  J Víšek; M Bláha; V Bláha; M Lášticová; M Lánska; C Andrýs; J Duintjer Tebbens; Ivone Cristina Igreja E Sá; K Tripská; M Vicen; I Najmanová; P Nachtigal
Journal:  Orphanet J Rare Dis       Date:  2021-02-27       Impact factor: 4.123

5.  Desialylation of platelet surface glycans enhances platelet adhesion to adsorbent polymers for lipoprotein apheresis.

Authors:  Lucia Lauková; René Weiss; Vladislav Semak; Viktoria Weber
Journal:  Int J Artif Organs       Date:  2020-11-03       Impact factor: 1.595

6.  Effects of Atorvastatin on Oxidative Stress Biomarkers and Mitochondrial Morphofunctionality in Hyperfibrinogenemia-Induced Atherogenesis.

Authors:  María de la Paz Scribano; María Del Carmen Baez; Becerra Florencia; Mariana Denise Tarán; Signorini Franco; Ariel G Balceda; Mónica Moya
Journal:  Adv Med       Date:  2014-10-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.